期刊文献+

骨保护素在血管钙化和骨质疏松关系中的重要作用 被引量:6

The Important Role of Osteoprotegerin in the Relationship between Vascular Calcification and Osteoporosis
原文传递
导出
摘要 目的探讨维持性血液透析患者骨密度、血管钙化和骨保护素(OPG)三者之间的关系及OPG在血管-骨对话机制中的作用。方法收集2010年5月-2012年12月行血液透析患者100例,采用X线平片检测患者血管钙化情况并评分,骨密度仪测定股骨颈骨密度,酶联免疫吸附法测定血清OPG水平,并检测患者一般生物化学指标,对各参数进行统计分析。结果 100例患者中血管钙化的检出率为74%(74/100),并且随着血管钙化程度的加重,OPG水平逐渐增高,差异有统计学意义(P<0.05)。100例患者中骨密度正常组40例,骨密度异常组60例,后者OPG水平明显高于前者,两组比较差异有统计学意义(P<0.05)。无血管钙化组的骨密度异常检出率(23.1%)明显低于血管钙化组的骨密度异常检出率(73.0%)。多重线性回归分析显示血管钙化评分、OPG水平、年龄是骨密度值的独立影响因素;透析时间、OPG水平、血白蛋白、骨密度值是血管钙化评分的独立影响因素。结论维持性血液透析患者血管钙化的同时常伴随骨质疏松,OPG在血管钙化和骨质疏松关系的发生发展过程中起了重要作用。 Objective To investigate the relationship among bone density, osteoprotegerin (OPG) and vascular calcification (VC) in maintenance hemodialysis (MHD) patients. Methods One hundred MHD patients were collected from our department between May 2010 and December 2012. The VC was detected by plain radiographs. Bone mineral density was measured with dual-energy X-ray absorptionmeter. The level of serum OPG was measured by enzyme- linked immunosorbent assay. Other clinically related indicators were also detected. The related parameters were examined statistically. Results The incidence of VC in MHD patients was 74% (74/100), and the OPG level significantly increased with the degree of vascular calcification (P 〈 0.05). The proportion of patients with normal bone volume was 40%, and with abnormal bone volume was 60%. Compared with patients with normal bone volume, the patients with abnormal bone volume had higher serum OPG level (P 〈 0.05). The patients with no VC had a lower incidence of abnormal bone volume than patients with VC (P 〈 0.05). Multiple linear regression analysis revealed that vascular calcification score, OPG level and age were independent factors for bone mineral density. Dialysis time, OPG level, serum albumin level and bone mineral density were independent factors for vascular calcification score. Conclusions The MHD patients with vascular calcification are often associated with osteoporosis at the same time. OPG plays an important role in the relationship between vascular calcification and osteoporosis.
出处 《华西医学》 CAS 2014年第7期1220-1223,共4页 West China Medical Journal
基金 泰兴市人民医院院校级基金项目(TRY1102)~~
关键词 维持性血液透析 骨保护素 血管钙化 骨密度 Maintenance hemodialysis Osteoprotegerin Vascular calcification Bone mineral density
  • 相关文献

参考文献20

  • 1Aoki A, Kojima F, Uchida K, et al. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients[J]. Geriatr Gerontol Int, 2009, 9(3): 246-252.
  • 2Adragao T, Herberth J, Monier-Faugere MC, et al. Low bone volume-a risk factor for coronary calcifications in hemodialysis patients[J]. Clin J Am Soc Nephrol, 2009, 4(2): 450-455.
  • 3Aoyagi K, Ross PD, Orloff J, et al. Low bone density is not associated with aortic calcification[J]. Calcif Tissue Int, 2001, 69(1): 20-24.
  • 4Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification[J]. Genes Dev, 1998, 12(9): 1260-1268.
  • 5Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients[J]. Nephrol Dial Transplant, 2004, 19(6): 1480-1488.
  • 6Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997, 89(2): 309-319.
  • 7Tousoulis D, Siasos G, Maniatis K, et al. Novel biomarkers assessing the calcium deposition in coronary artery disease[J]. Curr Med Chem, 2012, 19(6): 901-920.
  • 8Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives[J]. Oncogene, 2006, 25(51): 6680-6684.
  • 9Bekker P J, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women[J]. J Bone Miner Res, 2001, 16(2): 348-360.
  • 10袁瑞丽,刘钢.骨保护素与类风湿关节炎[J].华西医学,2008,23(3):653-654. 被引量:1

二级参考文献35

  • 1Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance Tcell growth and dendritic-cell function. Nature, 1997,13: 175-179.
  • 2Mesquita M, Wittersh eim E, Demulder A, et al. Bone cytokeines and renal osteodysrophy in peritoneal dialysis patients. Adv Petit Dial, 2005,21:184-184.
  • 3Kazama JJ, Shigematsu T, Yana K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J kidney Dis, 2002,39:525-532.
  • 4McHugh activator promotes Physiol, NA, Vercesi HM, Egan RW, et al. Receptor of NF-[kappa]B ligand arrests bone growth and cortical bone resorption in growing rats. J Appl 2003,95:672-680.
  • 5Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology [J]. J Mol Med, 2005, 83 (3): 170- 179.
  • 6Pierer M, Rethage J, Seibl R, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll - like receptor 2 ligands [J]. J Immunol, 2004, 172: 1256- 1265.
  • 7Kim KW, Cho ML, Lee SH, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RAN- KL via TLR - 2 and TLR - 4 activation [J]. Immunol Lett, 2007, 110 (1): 54-64.
  • 8Brechter AB, Lmer UH. Bradykinin potentiates cytokine-induced pmstaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in incresed RANKL expression [J]. Arthritis Rheum, 2007, 56 (3): 910-923.
  • 9Mrak E, Villa I, Lanzi R, et al. Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast - like cells [J]. J Endoerinol, 2007, 192 (3): 639 - 645.
  • 10Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of the adnfinistration of eortieosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins [J].J Mol Histol, 2007, 38 (3): 215-226.

共引文献4

同被引文献37

  • 1生杰,赵久阳.慢性肾脏病患者钙磷代谢紊乱与心瓣膜钙化[J].中国血液净化,2012,11(2):99-101. 被引量:13
  • 2姚静,侯加法.OPG/RANKL/RANK系统的研究进展[J].动物医学进展,2006,27(2):5-9. 被引量:25
  • 3Sarnak MJ. Cardiovascular complications in chronic kidney disease [J]. Am J Kid- ney Dis,2003,41 (5 Suppl): 11-17.
  • 4Kanis JA. Assessment of fracture risk and its application to screening for postmeno- pausal osteoporosis: synopsis of a WHOreport. WHO Study Group [J]. Osteoporos Int, 1994,4(6):368-381.
  • 5Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclasto genesis and bone disease[J]. Trends MolMed,2006,12(1):1 7-25.
  • 6Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted pro- tein involved in the regulation of bone density [J].Cell, 1997,89(2):309-319.
  • 7Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cellsurvival and bone remodeling [J]. Exp Oncol,2004,26(3): 179-184.
  • 8Shapses SA, Cifuentes M, Spevak L, et al. Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium deficiency [J]. Calcif Tissue Int,2003,73(1):86-92.
  • 9刘晓霞,张金凤.骨保护蛋白水平与心血管疾病关系的研究进展[J].河北医药,2008,30(6):862-863. 被引量:1
  • 10齐永芬.关注血管钙化和骨质疏松共同发病机制[J].中国动脉硬化杂志,2009,17(4):253-255. 被引量:8

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部